Finance

Lists
Why is LXEO up 6,66%?
Dive Deeper
LXEO:NASDAQ
Lexeo Therapeutics Inc
3,60 $
+6,66%
(+0,22) 1D
1 հոկ, 15:14:46 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for LXEO...
Open
3,38 $
High
3,68 $
Low
3,30 $
Mkt. cap
295,94 մլն
Avg. vol.
1,23 մլն
Volume
1,51 մլն
52-wk high
10,99 $
52-wk low
2,98 $
EPS
-1,16 $
Shares outstanding
82,09 մլն
No. of employees
63
Open
3,38 $
High
3,68 $
Low
3,30 $
Mkt. cap
295,94 մլն
Avg. vol.
1,23 մլն
Volume
1,51 մլն
52-wk high
10,99 $
52-wk low
2,98 $
EPS
-1,16 $
Shares outstanding
82,09 մլն
No. of employees
63
News stories
From web sources and news partners
About Lexeo Therapeutics Inc
CEO-
Employees63
Founded2017
Headquarters-
Sector-
Analyst ratings
Based on 4 analysts giving stock ratings to LXEO in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for LXEO in the last 3 months.
Highest
Current 3,60 $
20,00 $ (+454,79%)
Average
18,00 $ (+399,31%)
Lowest
15,00 $ (+316,09%)
Analyst
Recommendation
Action
Price target
Projected
Date
Unknown Analyst
Leerink Partners
Buy
Reiterated
15,00 $
+316,1%
09/23/2026
Leland Gershell
Oppenheimer
Buy
Reiterated
20,00 $
+454,8%
09/23/2026
Luca Issi
RBC Capital
Buy
Maintained
20,00 $
+454,8%
08/12/2026
Paul Matteis
Stifel Nicolaus
Buy
Maintained
17,00 $
+371,6%
07/06/2026
Tessa Romero
J.P. Morgan
Buy
Maintained
9,00 $
+149,7%
06/25/2026
Unknown Analyst
Stifel Nicolaus
Buy
Maintained
17,00 $
+371,6%
05/12/2026
Geulah Livshits
Chardan Capital
Buy
Reiterated
17,00 $
+371,6%
05/11/2026
Kristen Kluska
Cantor Fitzgerald
Buy
Maintained
19,00 $
+427%
03/30/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
10,00 $
+177,4%
01/13/2026
Christopher Raymond
Raymond James
Buy
Maintained
25,00 $
+593,5%
01/13/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
Revenue
-
-
-
-
Cost of goods sold
15,70 մլն
16,21 մլն
15,70 մլն
19,03 մլն
Cost of revenue
15,70 մլն
16,21 մլն
15,70 մլն
19,03 մլն
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5,95 մլն
6,91 մլն
6,63 մլն
8,99 մլն
Operating expense
5,95 մլն
6,91 մլն
6,63 մլն
8,99 մլն
Total operating expenses
21,65 մլն
23,12 մլն
22,33 մլն
28,02 մլն
Operating income
-21,65 մլն
-23,12 մլն
-22,33 մլն
-28,02 մլն
Other non operating income
-9,00 հզր
9,00 հզր
-1,00 հզր
-6,00 հզր
EBT including unusual items
-20,28 մլն
-20,92 մլն
-20,20 մլն
-25,87 մլն
EBT excluding unusual items
-20,22 մլն
-20,91 մլն
-20,24 մլն
-25,85 մլն
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-20,28 մլն
-20,92 մլն
-20,20 մլն
-25,87 մլն
Net profit margin
-
-
-
-
Earnings per share
-0,33
-0,27
-0,25
-0,30
Interest and investment income
1,46 մլն
2,21 մլն
2,11 մլն
2,19 մլն
Interest expense
-22,00 հզր
-20,00 հզր
-17,00 հզր
-14,00 հզր
Net interest expenses
1,43 մլն
2,19 մլն
2,10 մլն
2,18 մլն
Depreciation and amortization charges
-
-
-
-
EBITDA
-21,50 մլն
-22,96 մլն
-22,18 մլն
-27,87 մլն
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google Apps